Abstract Library

#4647 Crosstalk between cancer-associated fibroblasts and small intestinal neuroendocrine tumour cells in a 3D spheroid model

Introduction: At diagnosis, over 50% of small intestinal neuroendocrine tumours (SI-NETs) have metastasised to the mesentery where they often induce extensive fibrosis. Recent studies highlight the crucial interaction between SI-NET cells and cancer-associated fibroblasts (CAFs) in the pathogenesis of mesenteric fibrosis (MF).

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, van Koetsveld P, Iyer A, Hofland J,

Keywords: mesenteric fibrosis, small intestinal neuroendocrine tumour, CAF,

#4626 Comparison of two prognostic models for the treatment of pancreatic NET with PRRT

Introduction: The efficacy and time to progression (TTP) following peptide receptor radionuclide therapy (PRRT) for pancreatic neuroendocrine tumours varies widely.

Conference:

Presenting Author: Papantoniou D

Authors: Tiensuu Janson E, Fröss-Baron K, Grönberg M, Ziolkowska B,

Keywords: prrt, pancreatic neuroendocrine tumour, predictive model,

#4579 Real-world effectiveness of lanreotide autogel in patients with advanced gastroenteropancreatic neuroendocrine tumours with antigen Ki-67 proliferation index above and below 10%: The KINETICS study

Introduction: The somatostatin analogue lanreotide is an established treatment option for patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) with a Ki-67 proliferation index (Ki-67)

Conference:

Presenting Author: Vandamme T

Authors: Vandamme T, Gerard L, Del Olmo-Garcia M, de Mestier L, Kiesewetter B,

Keywords: effectiveness, gastroenteropancreatic neuroendocrine tumour, GEP-NET, Ki-67 proliferation index, Ki-67, lanreotide, somatostatin analogue, somatostatin, real-world,

#4573 Digestive neuroendocrine tumours: Patterns, pathways, and progress in personalised management

Introduction: Digestive neuroendocrine tumours (NETs), though rare, are increasingly diagnosed with their incidence rising. Histopathological examination is crucial for diagnosis and grading, based on cell differentiation and proliferation index. Often diagnosed late due to non-specific symptoms, these tumours may present with hormone hypersecretion. Updated classifications now allow better risk stratification and tailored treatments. Advances in imaging, particularly PETscans with somatostatin analogues have improved NET diagnosis and monitoring.

Conference:

Presenting Author: Bensetti Houari A

Authors: Bensetti Houari A, Remouche H, Belkharoubi K,

Keywords: Digestive neuroendocrine tumour, octreoscan, multidisciplinary approach,

#4557 miR-1290 and miR-320c regulate cell proliferation and predict patient prognosis in neuroendocrine carcinomas

Introduction: The biology of neuroendocrine carcinomas (NECs) remains largely unknown, limiting the use of biomarkers for patient stratification and therapy response prediction in clinical practice.

Conference:

Presenting Author: Liverani C

Authors: Liverani C, Sgolacchia F, Bongiovanni A, Calabrese C, Vanni S,

Keywords: biomarker, miRNAs, neuroendocrine carcinoma,